Prognostic Factors in Elderly Patients with Acute Myeloid Leukaemia

References

• Brinker H. Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia. Scan. J. Haematol. 1982; 29: 241–249
   PubMedGoogle Scholar
• Ost A., Lindstrom P., Christensson B., Gyllenhammar H., Engstedt L. Acute leukaemia in a defined geographic area- Incidence, clinical history and prognosis. Scan. J. Haematol. 1984; 33: 160–170
   PubMedGoogle Scholar
• Sorensen J. T., Gerald K., Bodensteiner D., Holmes F. F. Effect of age on survival in acute leukaemia. Cancer 1993; 72: 1602–1606
   PubMed Web of Science ®Google Scholar
• Crosby W. H. To treat or not to treat acute granulocytic leukaemia. Archives of Internal Med. 1968; 122: 79–80
   PubMed Web of Science ®Google Scholar
• Liu Yin J. A., Johnson P. R. E., Davies J. M., Flanagan N. G., Gorst D. W., Lewis M. J. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br. J. Haematol. 1991; 79: 415–420
   PubMed Web of Science ®Google Scholar
• Hutchinsoninfield R. M.W. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br. J. Haematol. 1992; 80: 416–417
   Web of Science ®Google Scholar
• Lowenberg B., Zittoun R., Kerkhofs H., Jehn U., Abels J., Debusscher L., et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukaemia: A randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukaemia Group. J. Clin. Oncol. 1989; 7: 1268–1274
   PubMed Web of Science ®Google Scholar
• Montastruc M., Reiffers J., Stoppa A. M., Sotto J. J., Corront B., Marit G., et al. Treatment of acute myeloid leukaemia in elderly patients: The influence of maintenance therapy (BGM 84 protocol). Nouvelle Revue Francois D'Hematologic 1990; 32: 147–152
   PubMed Web of Science ®Google Scholar
• Rees J. K. H., Gray R. G., Swirsky D., Hayhoe F. G. J. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; ii: 1236–1241
   Google Scholar
• Johnson P. R. E., Liu Yin J. A. Acute myeloid leukaemia in the elderly: Biology and treatment. Br. J. Haematol 1993; 83: 1–6
   PubMed Web of Science ®Google Scholar
• Baudard M., Marie J. P., Cadiou M., Viguie F., Zittoun R. Acute myelogenous leukaemia in the elderly: Retrospective study of 235 consecutive patients. Br. J. Haematol. 1994; 86: 82–91
   PubMed Web of Science ®Google Scholar
• Stone R. M., Mayer R. J. The approach to the elderly patient with acute myeloid leukaemia. Haematology/Oncology Clinics of North America 1993; 7: 65–79
   PubMed Web of Science ®Google Scholar
• Copplestone J. A., Prentice A. G. Acute myeloblasts leukaemia in the elderly. Leu. Res. 1988; 12: 617–625
   PubMed Web of Science ®Google Scholar
• Sebban C., Archimbaud E., Coiffier B., et al. Treatment of acute myeloid leukaemia in elderly patients: a retrospective study. Cancer 1988; 61: 227–231
   PubMed Web of Science ®Google Scholar
• Siddiqui T., Durkin W., Favis G., Smith A., Weiss R., Doughney K., Conley S. Management and outcome of AML in a community setting with a large geriatic population. Blood 1993; 82(Suppl 1), Abstract 2175
   Google Scholar
• Copplestone J. A., Smith A. G., Osmond C., Oscier D. G., Hamblin T. J. Treatment of acute myeloid leukaemia in the elderly: A clinical dilemma. Haematological Oncol. 1989; 7: 53–59
   PubMed Web of Science ®Google Scholar
• Toronto Leukaemia Study Group. Results of chemotherapy for unselected patients with acute myeloblasts leukaemia: Effect of exclusions on interpretation of results. Lancet 1986; i: 786–788
   Google Scholar
• Wahlin A., Hornsten P., Jonsson H. Remission rate and survival in acute myeloid leukaemia: Impact of selection and chemotherapy. Eur. J. Haematol 1991; 46: 240–247
   PubMed Web of Science ®Google Scholar
• Copplestone J. A., Smith A. G., Oscier D. G., Hamblin T. J. True outlook in acute myeloblasts leukaemia. Lancet 1986; i: 1104
   Google Scholar
• North West Regional Study of Acute Leukaemia in Adults. 1992, Annual Report
   Google Scholar
• Cox D. R. Regression models and life tables. J. Royal Statistical Soc. B 1972; 34: 187–220
   Google Scholar
• Bernard P., Lacombe F., Reiffers J., David B., Marit D. G., Bourdeau M. J., Broustet A. Relationship between patient's age, bone marrow karyotype, and outcome of induction therapy in acute myelogenous leukaemia. Am. J. Haematol 1985; 18: 153–158
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Barlogie B., Keating M. J., Hall R. R., Smith T. L., McCredie K. B., Freireich E. J. Pretreatment cy-tokinetics in acute myelogenous leukaemia: Age-related prognostic implications. J. Clin. Invest. 1985; 76: 319–324
   PubMed Web of Science ®Google Scholar
• Holmes F. F., Hearne E., Conant M., Garlow W. Survival in the elderly with acute leukaemia. J. Geriatrics Soc 1979; 27: 241–243
   Web of Science ®Google Scholar
• Reiffers J., Raynal F., Broustet A. Acute myeloblasts leukaemia in elderly patients: treatment and prognostic factors. Cancer 1980; 45: 2816–2820
   PubMed Web of Science ®Google Scholar
• Keating M. J., McCredie K. B., Benjamin R. S., et al. Treatment of patients over 50 years of age with acute myelogenous leukaemia with a combination, of rubidazone and cytosine arabi-noside, vincristine and prednisolone (ROAP). Blood 1981; 58: 584–591
   PubMed Web of Science ®Google Scholar
• Vogler W. R., Raney M., Winton E. F. Prognostic variables in acute myelogenous leukaemia (AML) in the elderly. Proc. Am. Soc. Clin. Oncol. 1983; 2: 172
   Google Scholar
• Walters R. S., Kantarjian H. M., Keating M. J., Estey E. H., McCredie K. B., Freireich E. J. Intensive treatment of acute leukaemia in adults 70 years of age and older. Cancer 1987; 60: 149–155
   PubMed Web of Science ®Google Scholar
• Tucker S., Thomas A. E., Gregory W. M., et al. Acute myeloid leukaemia in elderly patients. Haematological Oncol. 1990; 8: 13–21
   PubMed Web of Science ®Google Scholar
• Burke H. B., Henson D. E. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 1993; 72: 3131–3135
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Larson R. A., Raza A., Browman G., Goldberg J., Vogler R., Day R., Gottlieb A., Vardiman J. W., Bennett J., Kukla C., Grunwald H. The treatment of patients with newly diagnosed acute myelogenous leukaemia: Response to treatment and treatment failure. Br. J. Haematol. 1991; 79: 390–397
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Priore R., Azarnia N., et al. Prediction of response of patients with acute non-lymphocytic leukaemia to remission induction therapy: use of clinical measurements. Br. J. Haematol. 1986; 63: 625–636
   PubMed Web of Science ®Google Scholar
• Estey E., Smith T. L., Keating M. J., McCredie K. B., Gehan E. A., Freireich E. J. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblasts leukaemia. Leukaemia 1989; 3: 257–263
   PubMed Web of Science ®Google Scholar
• Johnson P. R. E., Hunt L. P., Liu Yin J. A. Prognostic factors in elderly patients with acute myeloid leukaemia: Development of a model to predict survival. Br. J. Haematol. 1993; 95: 300–306
   Web of Science ®Google Scholar
• Hoyle C. F., Gray R. G., Wheatley K., et al. Prognostic importance of Sudan Black positivity: A study of bone marrow slides from 1386 patients with de-novo acute myeloid leukaemia. Br. J. Haematol. 1991; 79: 398–407
   PubMed Web of Science ®Google Scholar
• Hamblin T. The treatment of acute myeloid leukaemia preceded by the myelodysplastic syndrome. Leu. Res. 1992; 16: 101–108
   PubMed Web of Science ®Google Scholar
• San Miguel J. F., Hernandez J. M., Gonzalez-Sarmiento R., Gonzalez M., Sanchez I., Orfao A., Canizo M. C., Lopez Borrasca A. Acute leukaemia after a primary myelodysplastic syndrome: Immunophenoty pic, genotypic, and clinical characteristics. Blood 1991; 78: 768–774
   PubMed Web of Science ®Google Scholar
• Gajewski J. L., Ho W. G., Nimer S. D., Hirji K. F., Gekelman L., Jacobs A. D., Champlin R. E. Efficacy of intensive chemotherapy for acute myelogenous leukaemia associated with a preleukaemic syndrome. J. Clin. Oncol. 1989; 7: 1637–1645
   PubMed Web of Science ®Google Scholar
• Groupe Francais de Cytogenetique Hematologique (GFCH). Acute leukaemia treated with intensive chemotherapy in patients with a history of previous chemo- and/or radiotherapy: Prognostic significance of karyotype and preceding myelodysplastic syndrome. Leukaemia, S 1994; 87–91
   Google Scholar
• Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glyco-protein expression on acute nonlymphoblastic leukaemia cells at diagnosis. Blood 1992; 79: 473–476
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle F., Catovsky D., Galton D. A. G. Clinical and laboratory features of de-novo acute myeloid leukaemia with trilineage myelodysplasia. Br. J. Haematol. 1987; 66: 445–450
   PubMed Web of Science ®Google Scholar
• Johnson P. R. E., Liu Yin J. A. The influence of clinical or morphological myelodysplasia on the outcome of therapy in elderly patients with acute myeloid leukaemia. Haematologica 1991; 76(Suppl 4), Abstract 511
   Google Scholar
• Goasguen J. E., Matsuo T., Cox C., Bennett J. M. Evaluation of the dysmyelopoiesis in 336 patients with de-novo acute myeloid leukaemia: Major importance of dysgranulopoiesis for remission and survival. Leukaemia 1992; 6: 520
   PubMed Web of Science ®Google Scholar
• Goasguen J. E., Buchner T., Hiddemann W., Wormann B., Heinecke A., Sauerland M. C., Fonatsch C., Becher R., Hossfeld D., Loffler H., Schaefer U. W. Prognostic importance of myeloid dysplastic features in AML. Blood 1993; 82(Suppl 1), Abstract 483
   Google Scholar
• Ballen K. K., Gilliland D. G., Kalish L. A., Shulman L. N. Bone marrow dysplasia in patients with newly diagnosed acute myelogenous leukaemia does not correlate with history of myelodysplasia or with remission rate and survival. Cancer 1993; 73: 314–321
   Web of Science ®Google Scholar
• Hellstrom-Lindberg E., Robert K.-H., Gahrton G., Lindberg G., Forsblom A.-M., Kock Y., Ost A. A predictive model for the clinical response to low dose Ara-C: A study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br. J. Haematol 1992; 81: 503–511
   PubMed Web of Science ®Google Scholar
• Ogata K., Yamada T., Ito T., Gomi S., Tanabe Y., Ohki I., Dan K., Nomura T. Low-dose etoposide: A potential therapy for myelodysplastic syndromes. Br. J. Haematol 1992; 82: 354–357
   PubMed Web of Science ®Google Scholar
• FIWCL 1984 Fourth International Workshop on Chromosomes in Leukaemia, 1982. Overview of association between chromosome pattern and cell morphology, age, sex, and race. Cancer Genetics and Cytogenetics 1984; II: 265–274
   Google Scholar
• Schiffer C. A., Lee E. J., Tomiyasu T., Wiemik P. H., Testa J. R. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukaemia. Blood 1989; 73: 263–270
   PubMed Web of Science ®Google Scholar
• Stasi R., Del Poeta G., Masi M., Tribalto M., Venditti A., Papa G., et al. Incidence of chromosomal abnormalities and clinical significance of karyotype in de novo acute myeloid leukaemia. Cancer Genetics and Cytogenetics 1993; 67: 28–34
   PubMed Web of Science ®Google Scholar
• Fenaux P., Lai J. L., Gardin C., Bauters F. Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukaemia (AML) in the elderly. Leukaemia 1990; 4: 312
   PubMed Web of Science ®Google Scholar
• Van Slyck E. J., Rebuck J. W., Waddell C. C., Janakiraman N. Smouldering acute granulocytic leukaemia: Observations on its natural history and morphological characteristics. Archives of Internal Med. 1983; 143: 37–40
   PubMed Web of Science ®Google Scholar